Russia's Natsimbio to invest $100 million in establishment of vaccines production in Ufa

20 November 2017

The National Immunobiological Company, Natsimbio, Russia’s leading vaccines’ producer, plans to invest 6 billion roubles (~$100 million) in the construction of a plant for the production of vaccines in the Russian city of Ufa, according to recent statements of the company's general director Maryam Khubieva.

The project will be implemented by Natsimbio’s subsidiary Microgen, reports The Pharma Letter’s local correspondent.

The plant will produce vaccines for the national calendar of preventive vaccinations, as well as drugs that Microgen plans to produce as part of the technology transfer.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK